Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) has provided an update.
ESSA Pharma Inc. announced that its securityholders have approved the acquisition of all its common shares by XenoTherapeutics Inc., a non-profit biotechnology company, through a statutory plan of arrangement. The approval was overwhelmingly supported by the securityholders, with the arrangement subject to the approval of the Supreme Court of British Columbia and other customary closing conditions. The transaction is expected to be completed by October 9, 2025, marking a significant shift in ESSA’s operational focus and potentially impacting its stakeholders.
The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. XenoTherapeutics Inc. is a Massachusetts-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education.
Average Trading Volume: 6,535,786
Technical Sentiment Signal: Sell
Current Market Cap: $9.75M
Find detailed analytics on EPIX stock on TipRanks’ Stock Analysis page.